Myriad Genetics Inc
MYGN8.180USD
+0.140+1.74%
Handelsschluss 11/03, 16:00（ET）Kurse um 15 Minuten verzögert
761.56MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Myriad Genetics Inc Unternehmen
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
Myriad Genetics Inc Informationen
BörsenkürzelMYGN
Name des UnternehmensMyriad Genetics Inc
IPO-datumOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Anzahl der mitarbeiter2700
WertpapierartOrdinary Share
GeschäftsjahresendeOct 06
Addresse322 North 2200 West
StadtSALT LAKE CITY
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl84116
Telefon18015843600
Websitehttps://myriad.com/
BörsenkürzelMYGN
IPO-datumOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Führungskräfte von Myriad Genetics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
92.65K
-2.69%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
Nach RegionUSD
Name
Umsatz
Anteil
United States
198.20M
93.01%
Rest of world
14.90M
6.99%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
Aktionärsstatistik
Aktualisiert: Wed, Oct 8
Aktualisiert: Wed, Oct 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.43%
The Vanguard Group, Inc.
8.47%
Millennium Management LLC
5.29%
State Street Investment Management (US)
5.17%
Glenview Capital Management, LLC
4.93%
Andere
61.70%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.43%
The Vanguard Group, Inc.
8.47%
Millennium Management LLC
5.29%
State Street Investment Management (US)
5.17%
Glenview Capital Management, LLC
4.93%
Andere
61.70%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
37.21%
Hedge Fund
27.56%
Investment Advisor/Hedge Fund
25.31%
Research Firm
6.02%
Individual Investor
3.32%
Pension Fund
1.88%
Bank and Trust
0.41%
Venture Capital
0.31%
Family Office
0.08%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
515
91.89M
98.76%
-9.78M
2025Q2
518
100.80M
108.34%
-1.85M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
13.43M
14.43%
-416.99K
-3.01%
Jun 30, 2025
The Vanguard Group, Inc.
9.15M
9.83%
-1.47M
-13.83%
Jun 30, 2025
Millennium Management LLC
4.92M
5.29%
+855.19K
+21.01%
Jun 30, 2025
State Street Investment Management (US)
4.81M
5.17%
-458.84K
-8.71%
Jun 30, 2025
Glenview Capital Management, LLC
4.59M
4.93%
+687.86K
+17.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
4.51M
4.85%
+1.99M
+78.84%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
3.63%
+1.97M
+140.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.22M
2.39%
-7.80K
-0.35%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.07M
2.23%
-139.99K
-6.33%
Jun 30, 2025
Qube Research & Technologies Ltd
2.05M
2.21%
+633.44K
+44.67%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
WisdomTree BioRevolution Fund
0.81%
Federated Hermes MDT Small Cap Core ETF
0.74%
Global X Genomics & Biotechnology ETF
0.74%
Invesco NASDAQ Future Gen 200 ETF
0.55%
Invesco S&P SmallCap Health Care ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.26%
Strategas Global Policy Opportunities ETF
0.23%
SPDR S&P Biotech ETF
0.21%
Vanguard US Quality Factor ETF
0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
Mehr Anzeigen
WisdomTree BioRevolution Fund
Anteil0.81%
Federated Hermes MDT Small Cap Core ETF
Anteil0.74%
Global X Genomics & Biotechnology ETF
Anteil0.74%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.55%
Invesco S&P SmallCap Health Care ETF
Anteil0.43%
Inspire Small/Mid Cap ESG ETF
Anteil0.26%
Strategas Global Policy Opportunities ETF
Anteil0.23%
SPDR S&P Biotech ETF
Anteil0.21%
Vanguard US Quality Factor ETF
Anteil0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.12%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
